Comparison of infrared spectra of CLL cells with their ex vivo sensitivity (MTT assay) to chlorambucil and cladribine

  1. Get@NRC: Comparison of infrared spectra of CLL cells with their ex vivo sensitivity (MTT assay) to chlorambucil and cladribine (Opens in a new window)
DOIResolve DOI:
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for:
Journal titleLeukemia Research
Pages11251133; # of pages: 9
SubjectChronic lymphocytic leukemia; chlorambucil; cladribine (2-chlorodeoxyadenosine); drug resistance; FT-IR spectroscopy; Negative therapeutic reaction; Alkylating agent; Purine nucleoside; Cytotoxicity; Malignant hemopathy; Lymphoproliferative syndrome; cladribine (2-chlorodeoxyadenosine); Spectrométrie FT-IR; Leucémie lymphoïde; chlorambucil; Résistance traitement; Purine nucléoside; Agent alkylant; Cytotoxicité; Hémopathie maligne; Lymphoprolifératif syndrome
AbstractThe drug resistance of leukemic cells from 21 patients with chronic lymphocytic leukemia (CLL) to the alkylating agent chlorambucil (CLB) and the nucleoside analog cladribine or 2-chlorodeoxyadenosine (CdA) was investigated by infrared spectroscopy. Drug sensitivities, determined in vitro with the tetrazolium dye (MTT) assay, were correlated with the infrared spectra of the CLL cells, applying linear discriminant analysis (LDA). The 63 spectra (three from each of the 21 samples), obtained before drug exposure, were successfully partitioned into drug-sensitive and drug-resistant groups; the LDA-based ex vivo prediction of the sensitivity to CdA or CLB was 85.7% and 80.3%, respectively. Similar changes in the composition/structure of DNA were observed between the spectra of the drug-sensitive and drug-resistant CLL cells for both CdA and CLB. However, CdA-resistant CLL cells could also be differentiated from CdA-sensitive CLL cells by spectral changes associated with membrane lipids; these differences were much less pronounced between CLB-resistant and CLB-sensitive CLL cells. We demonstrate here for the first time that infrared spectroscopy can be used as a new tool for predicting ex vivo drug response (sensitivity/resistance).
Publication date
PublisherElsevier B.V.
Copyright noticeYou may reproduce (print, make photocopies, or download) materials from NPArC without permission for non-commercial purposes (research, education, and private study), on the condition that you provide proper attribution of the sources in all copies.
AffiliationNRC Institute for Biodiagnostics (IBD-IBD); National Research Council Canada
Access conditionavailable
Peer reviewedYes
NRC number498
NPARC number9201848
Export citationExport as RIS
Report a correctionReport a correction
Record identifierd8338c03-b26d-4541-b21c-211f7ffbe8d5
Record created2009-10-02
Record modified2016-10-28
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)
Date modified: